Value of modified albumin-bilirubin grade in predicting the prognosis of patients with Child-Pugh class A unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization combined with immunotherapy and anti-angiogenic drugs

Jiaqing LI; Xiaoyang XU; Zexin HU; Shen ZHANG; Binyan ZHONG; Xiaoli ZHU

doi:10.12449/JCH241215

Volume 40 Issue 12

Dec. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(12): 2450-2456

PDF( 856 KB)

Value of modified albumin-bilirubin grade in predicting the prognosis of patients with Child-Pugh class A unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization combined with immunotherapy and anti-angiogenic drugs

DOI: 10.12449/JCH241215

Department of Interventional Radiology，The First Affiliated Hospital of Soochow University，Suzhou，Jiangsu 215000，China

Research funding:

General Project of Jiangsu Provincial Natural Science Foundation (SBK2023022210);

Key R&D Program （Social Development） of Jiangsu Provincial Department of Science and Technology (BE2021648)

More Information

Corresponding author: ZHU Xiaoli， zhuxiaoli90@163.com （ORCID： 0000-0002-3507-2018）
Received Date: 2024-03-01
Accepted Date: 2024-04-22
Published Date: 2024-12-25

Abstract

Abstract

Objective To investigate the ability of the modified albumin-bilirubin （mALBI） grade in predicting the prognosis of patients with Child-Pugh A unresectable hepatocellular carcinoma （uHCC） after transcatheter arterial chemoembolization （TACE） combined with immunotherapy and anti-angiogenic drugs （hereafter referred to as targeted immunotherapy）. Methods A retrospective analysis was performed for the data of 76 patients with Child-Pugh A uHCC who met the inclusion criteria and underwent TACE combined with targeted immunotherapy in The First Affiliated Hospital of Soochow University from January 2020 to January 2023， and according to the mALBI grade， they were divided into mALBI 1/2a group with 38 patients and mALBI 2b group with 38 patients. The primary endpoint was overall survival （OS）， and the secondary endpoints were progression-free survival （PFS）， objective response rate （ORR）， and disease control rate （DCR）. Evaluation criteria included complete remission， partial remission， stable disease， and progressive disease. The independent-samples t test was used for comparison of normally distributed continuous data between groups， and the Wilcoxon rank-sum test was used for comparison of non-normally distributed continuous data between groups； the chi-square test was used for comparison of categorical variables between two groups. The Kaplan-Meier method was used to plot survival curves， and the Log-rank test was used for comparison of median OS （mOS） and median PFS （mPFS） between groups. The univariate and multivariate Cox proportional hazards models were used to analyze the influencing factors for prognosis. Results There were significant differences in albumin and tumor burden between the two groups （both P<0.05）. The 76 patients had an mOS of 25.2 months （95% confidence interval ［CI］： 18.4 — 32.0）， an mPFS of 9.4 months （95%CI： 7.1 — 11.7）， an ORR of 63.2%， and a DCR of 82.9%. The mOS was 30.1 months （95%CI： 19.8 — 40.4） in the mALBI 1/2a group and 19.5 months （95%CI： 7.1 — 31.9） in the mALBI 2b group， and there was a significant difference in mOS between the two groups （χ²=4.490， P=0.034）. The mALBI 1/2a group had an mPFS of 10.2 months （95%CI： 8.4 — 12.0）， an ORR of 71.1%， and a DCR of 86.8%， while the mALBI 2b group had an mPFS of 7.6 months （95%CI： 4.6 — 10.6）， an ORR of 55.3%， and a DCR of 78.9%； there were no significant differences in mPFS， ORR， and DCR between the two groups （all P>0.05）. ECOG status， tumor burden， mALBI grade， portal vein invasion， and extrahepatic metastasis were independent risk factors for mOS in patients undergoing TACE combined with targeted immunotherapy （all P<0.05）. There were no treatment-related deaths. Conclusion The mALBI grade has a good value in predicting the survival of patients with Child-Pugh A uHCC undergoing TACE combined with targeted immunotherapy.
- Carcinoma， Hepatocellular,
- Chemoembolization， Therapeutic,
- mALBI Grade

FullText(HTML)

References(33)

References

[1]	ZHOU MG, WANG HD, ZENG XY, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394( 10204): 1145- 1158. DOI: 10.1016/S0140-6736(19)30427-1.
[2]	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68( 6): 394- 424. DOI: 10.3322/caac.21492.
[3]	General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer(2022 edition)[J]. J Clin Hepatol, 2022, 38( 2): 288- 303. DOI: 10.3969/j.issn.1001-5256.2022.02.009. 国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38( 2): 288- 303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
[4]	ZHU HD, LI HL, HUANG MS, et al. Transarterial chemoembolization with PD-(L)₁ inhibitors plus molecular targeted therapies for hepatocellular carcinoma(CHANCE001)[J]. Signal Transduct Target Ther, 2023, 8( 1): 58. DOI: 10.1038/s41392-022-01235-0.
[5]	SANGRO B, KUDO M, QIN S, et al. A phase 3, randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab therapy in patients with locoregional hepatocellular carcinoma: EMERALD-1[J]. Ann Oncol, 2020, 31: S202- S203. DOI: 10.1016/j.annonc.2020.04.429.
[6]	XIN YJ, ZHANG XY, LIU N, et al. Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma[J]. Hepatol Int, 2023, 17( 3): 753- 764. DOI: 10.1007/s12072-023-10502-3.
[7]	Liver Oncology Branch, China Association for the Promotion of International Exchange in Healthcare; Branch Immunology, China Association for the Promotion of International Exchange in Healthcare; Cooperative Group for Chinese Expert Consensus on Targeted Immunotherapy Combined with Local Therapy for Advanced Hepatocellular Cancer. Chinese expert consensus on targeted immunotherapy combined with local therapy for advanced hepatocellular cancer[J]. J Clin Hepatol, 2023, 39( 12): 2782- 2792. DOI: 10.3969/j.issn.1001-5256.2023.12.006. 中国医疗保健国际交流促进会肝脏肿瘤学分会, 中国医疗保健国际交流促进会免疫学分会,《靶免联合局部治疗中晚期肝细胞癌中国专家共识》协作组. 靶向免疫联合局部治疗中晚期肝细胞癌中国专家共识[J]. 临床肝胆病杂志, 2023, 39( 12): 2782- 2792. DOI: 10.3969/j.issn.1001-5256.2023.12.006.
[8]	HIRAOKA A, KUMADA T, KUDO M, et al. Albumin-bilirubin(ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan society of hepatology: A comparison with the liver damage and Child-pugh classifications[J]. Liver Cancer, 2017, 6( 3): 204- 215. DOI: 10.1159/000452846.
[9]	JOHNSON PJ, BERHANE S, KAGEBAYASHI C, et al. Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach-the ALBI grade[J]. J Clin Oncol, 2015, 33( 6): 550- 558. DOI: 10.1200/JCO.2014.57.9151.
[10]	WANG YY, ZHONG JH, SU ZY, et al. Albumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma[J]. Br J Surg, 2016, 103( 6): 725- 734. DOI: 10.1002/bjs.10095.
[11]	WANG ZX, WANG EX, XIA DD, et al. Value of Child-Pugh score versus albumin-bilirubin grade in predicting the prognosis of unresectable hepatocellular carcinoma treated by transarterial chemoembolization[J]. J Clin Hepatol, 2020, 36( 1): 113- 117. DOI: 10.3969/j.issn.1001-5256.2020.01.025. 王哲轩, 王恩鑫, 夏冬东, 等. Child-Pugh评分和ALBI分级预测经肝动脉化疗栓塞治疗不可切除肝细胞癌预后的价值比较[J]. 临床肝胆病杂志, 2020, 36( 1): 113- 117. DOI: 10.3969/j.issn.1001-5256.2020.01.025.
[12]	KUMADA T, TOYODA H, TADA T, et al. Changes in background liver function in patients with hepatocellular carcinoma over 30 years: Comparison of child-pugh classification and albumin bilirubin grade[J]. Liver Cancer, 2020, 9( 5): 518- 528. DOI: 10.1159/000507933.
[13]	SUN Y, ZHANG HH, SHENG SP, et al. Prognostic significance of albumin-bilirubin grading in patients with early hepatocellular carcinoma after radiofrequency ablation treatment[J]. J Interv Radiol, 2021, 30( 5): 502- 507. DOI: 10.3969/j.issn.1008-794X.2021.05.018. 孙玉, 张洪海, 生守鹏, 等. 白蛋白-胆红素分级在早期肝细胞癌射频消融中的预后意义[J]. 介入放射学杂志, 2021, 30( 5): 502- 507. DOI: 10.3969/j.issn.1008-794X.2021.05.018.
[14]	LEE IC, HUNG YW, LIU CA, et al. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma[J]. Liver Int, 2019, 39( 9): 1704- 1712. DOI: 10.1111/liv.14194.
[15]	SAITO N, NISHIOFUKU H, SATO T, et al. Predictive factors of complete response to transarterial chemoembolization in intermediate stage hepatocellular carcinoma beyond up-to-7 criteria[J]. Cancers, 2023, 15( 9): 2609. DOI: 10.3390/cancers15092609.
[16]	HICKEY R, MOULI S, KULIK L, et al. Independent analysis of albumin-bilirubin grade in a 765-patient cohort treated with transarterial locoregional therapy for hepatocellular carcinoma[J]. J Vasc Interv Radiol, 2016, 27( 6): 795- 802. DOI: 10.1016/j.jvir.2016.03.005.
[17]	YU WM, HONG WQ, SUN BL, et al. Value of albumin-bilirubin grade in predicting liver function changes and prognosis of hepatocellular carcinoma patients undergoing transarterial chemoembolization: A Meta-analysis[J]. J Clin Hepatol, 2021, 37( 11): 2575- 2583. DOI: 10.3969/j.issn.1001-5256.2021.11.018. 余伟明, 洪文倩, 孙丙伦, 等. 白蛋白-胆红素分级对经肝动脉化疗栓塞术治疗肝癌患者肝功能变化及其预后评估价值的Meta分析[J]. 临床肝胆病杂志, 2021, 37( 11): 2575- 2583. DOI: 10.3969/j.issn.1001-5256.2021.11.018.
[18]	HIRAOKA A, KUMADA T, TSUJI K, et al. Validation of modified ALBI grade for more detailed assessment of hepatic function in hepatocellular carcinoma patients: A multicenter analysis[J]. Liver Cancer, 2019, 8( 2): 121- 129. DOI: 10.1159/000488778.
[19]	PINATO DJ, KANEKO T, SAEED A, et al. Immunotherapy in hepatocellular cancer patients with mild to severe liver dysfunction: Adjunctive role of the ALBI grade[J]. Cancers, 2020, 12( 7): 1862. DOI: 10.3390/cancers12071862.
[20]	KUDO M, FINN RS, CHENG AL, et al. Albumin-bilirubin grade analyses of atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma: A post hoc analysis of the Phase III IMbrave150 study[J]. Liver Cancer, 2023, 12( 5): 479- 493. DOI: 10.1159/000529996.
[21]	TANAKA K, TSUJI K, HIRAOKA A, et al. Usefulness of tumor marker score for predicting the prognosis of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A multicenter retrospective study[J]. Cancers, 2023, 15( 17): 4348. DOI: 10.3390/cancers15174348.
[22]	KELLEY RK, RIMASSA L, CHENG AL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma(COSMIC-312): A multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2022, 23( 8): 995- 1008. DOI: 10.1016/S1470-2045(22)00326-6.
[23]	KUDO M, GALLE PR, BRANDI G, et al. Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2[J]. JHEP Rep, 2021, 3( 2): 100215. DOI: 10.1016/j.jhepr.2020.100215.
[24]	LEE PC, CHEN YT, CHAO YE, et al. Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma[J]. Liver Int, 2018, 38( 2): 321- 330. DOI: 10.1111/liv.13527.
[25]	KUDO M. Newly developed modified ALBI grade shows better prognostic and predictive value for hepatocellular carcinoma[J]. Liver Cancer, 2022, 11( 1): 1- 8. DOI: 10.1159/000521374.
[26]	Clinical Guidelines Committee of Chinese College of Interventionalists. Expert consensus on the TACE failure/refractoriness and its subsequent therapies in treating patients with hepatocellular carcinoma[J]. J Interv Radiol, 2022, 31( 11): 1039- 1044. DOI: 10.3969/j.issn.1008-794X.2022.11.001. 中国医师协会介入医师分会临床诊疗指南专委会. 肝细胞癌经动脉化疗栓塞抵抗及后续治疗专家共识[J]. 介入放射学杂志, 2022, 31( 11): 1039- 1044. DOI: 10.3969/j.issn.1008-794X.2022.11.001.
[27]	LENCIONI R, LLOVET JM. Modified RECIST(mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30( 1): 52- 60. DOI: 10.1055/s-0030-1247132.
[28]	PARK JW, CHEN MS, COLOMBO M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: The BRIDGE Study[J]. Liver Int, 2015, 35( 9): 2155- 2166. DOI: 10.1111/liv.12818.
[29]	HSU WF, HSU SC, CHEN TH, et al. Modified albumin-bilirubin model for stratifying survival in patients with hepatocellular carcinoma receiving anticancer therapy[J]. Cancers, 2022, 14( 20): 5083. DOI: 10.3390/cancers14205083.
[30]	IIJIMA H, KUDO M, KUBO S, et al. Report of the 23^rd nationwide follow-up survey of primary liver cancer in Japan(2014-2015)[J]. Hepatol Res, 2023, 53( 10): 895- 959. DOI: 10.1111/hepr.13953.
[31]	AMIOKA K, KAWAOKA T, KINAMI T, et al. Analysis of lenvatinib’s efficacy against intermediate-stage unresectable hepatocellular carcinoma[J]. Cancers, 2022, 14( 20): 5066. DOI: 10.3390/cancers14205066.
[32]	REDDY KR, MCLERRAN D, MARSH T, et al. Incidence and risk factors for hepatocellular carcinoma in cirrhosis: The multicenter hepatocellular carcinoma early detection strategy(HEDS) study[J]. Gastroenterology, 2023, 165( 4): 1053- 1063. DOI: 10.1053/j.gastro.2023.06.027.
[33]	REIG M, FORNER A, RIMOLA J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update[J]. J Hepatol, 2022, 76( 3): 681- 693. DOI: 10.1016/j.jhep.2021.11.018.

Relative Articles

[1]	Huajie XIE, Kai CHANG, Yanyan WANG, Wanlin NA, Huan CAI, Xia LIU, Zhongyong JIANG, Zonghai HU, Yuan LIU. Characteristics of mitochondrial translational initiation factor 2 gene methylation and its association with the development of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2025, 41(2): 284-291. doi: 10.12449/JCH250214
[2]	Xiaoqin ZHU, Na WEI, Yong XIAO, Baoping YU. Impact of hepatocellular carcinoma on the prognosis of patients with liver cirrhosis undergoing emergency endoscopic therapy due to esophagogastric variceal bleeding[J]. Journal of Clinical Hepatology, 2025, 41(2): 277-283. doi: 10.12449/JCH250213
[3]	Lijuan LONG, Zongyu WANG, Yali ZHAO, Chuanfu QIN, Hua QIU. Research advances in traditional Chinese medicine for the treatment of hepatocellular carcinoma by regulating immune cells[J]. Journal of Clinical Hepatology, 2025, 41(2): 349-358. doi: 10.12449/JCH250223
[4]	Jiahao XU, Dongxu YIN, Yuchen LI, Fujie CHEN, Mingda WANG, Tian YANG. Systemic therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(11): 2306-2314. doi: 10.12449/JCH241127
[5]	Yanfang HE, Jiaojiao XIE, Lanlan ZHENG, Cai GUO, Yanhua MA. Expression and clinical significance of cell cycle protein-dependent kinase 1 and aurora kinase A in the serum of patients with hepatitis B virus-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(7): 1390-1396. doi: 10.12449/JCH240717
[6]	Kaifu LI, Yongcheng TANG, Hao TANG, Xi ZHANG, Benjian GAO, De LUO, Song SU, Bo LI, Xiaoli YANG. Efficacy and safety of three-dimensional visualization technology in assisting ablation therapy for hepatocellular carcinoma： A Meta-analysis[J]. Journal of Clinical Hepatology, 2024, 40(7): 1397-1403. doi: 10.12449/JCH240718
[7]	Changwang ZHANG, Ninghan WU, Cong WANG, Zheng ZHENG, Siming GAO, Changpeng ZOU, Sujing ZHANG, Na LI. Efficacy and safety of cryoablation combined with Camrelizumab monoclonal antibody in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(6): 1169-1174. doi: 10.12449/JCH240616
[8]	Chaofan ZHU, Xiaodong WANG. Value of local treatment combined with systemic therapy in conversion therapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(9): 1732-1737. doi: 10.12449/JCH240903
[9]	Teng LIU, Xiujuan CHANG, Quanwei HE, Ran XU, Yongping YANG. Efficacy and safety of cryoablation combined with lenvatinib and anti-PD-1 monoclonal antibody in treatment of unresectable hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(3): 539-549. doi: 10.12449/JCH240317
[10]	Jianxing LUO, Yang ZHANG, Ne XIANG, Xiaoyu HU. Efficacy and safety of microwave ablation versus hepatic resection in treatment of hepatocellular carcinoma with liver cirrhosis： A Meta-analysis[J]. Journal of Clinical Hepatology, 2024, 40(9): 1807-1815. doi: 10.12449/JCH240915
[11]	Shichun LU. Challenges and reflections on conversion therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(9): 1738-1740. doi: 10.12449/JCH240904
[12]	Chi MA, Guang TAN. Strategies and practice of conversion therapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(9): 1725-1731. doi: 10.12449/JCH240902
[13]	Chuyue ZHANG, Jianing SHI, Mingda WANG, Han WU, Lijun SHI, Tian YANG. Advances in the application of microspheres and nanoparticles in transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(4): 816-821. doi: 10.12449/JCH240428
[14]	Qianxin HUANG, Bin SHEN, Jinchang XIAO, Zhikang GAO, Duntao LYU, Yan LI, Hao XU, Qingqiao ZHANG. Efficacy of drug-eluting beads-transarterial chemoembolization combined with infusion chemotherapy via superior mesenteric artery in treatment of hepatocellular carcinoma complicated by portal vein tumor thrombus[J]. Journal of Clinical Hepatology, 2024, 40(12): 2457-2463. doi: 10.12449/JCH241216
[15]	Zexin HU, Jintao HUANG, Binyan ZHONG, Jian SHEN, Xiaoli ZHU. Current status and prospects of transarterial chemoembolization and its combined regimens in the treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(1): 175-180. doi: 10.12449/JCH240129
[16]	Zexin HU, Jiaqing LI, Wanci LI, Binyan ZHONG, Shuai ZHANG, Jian SHEN, Xiaoli ZHU. Efficacy and safety of transcatheter arterial chemoembolization combined with targeted therapy and immunotherapy in treatment of patients with stage Ⅱ‍b/Ⅲ‍a hepatocellular carcinoma based on China Liver Cancer Staging[J]. Journal of Clinical Hepatology, 2024, 40(3): 550-555. doi: 10.12449/JCH240318
[17]	Meng REN, Junxiu TAO, Ziming LI, Qi HAO, Yi YANG, Yufeng SHI, Yifan LIU, Yue XU, Tongtong ZHENG, Xiaodong LI. Influencing factors for compliance with hepatocellular carcinoma surveillance in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2023, 39(9): 2096-2102. doi: 10.3969/j.issn.1001-5256.2023.09.010
[18]	Liver Oncology Branch, China Association for the Promotion of International Exchange in Healthcare, Immunology Branch. Chinese expert consensus on targeted immunotherapy combined with local therapy for advanced hepatocellular cancer[J]. Journal of Clinical Hepatology, 2023, 39(12): 2782-2792. doi: 10.3969/j.issn.1001-5256.2023.12.006
[19]	Pengwei REN, Ying HAN, Xinmin ZHOU. Predictive indicators for the efficacy of targeted therapy/immunotherapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(11): 2705-2709. doi: 10.3969/j.issn.1001-5256.2023.11.028
[20]	Zhisong NI, Junhan WEN, Weiwei ZHAO, Shoujun YU, Liang HAO, Yu CHENG, Xin LIU. Neoadjuvant therapy for hepatocellular carcinoma： Current situation and prospects[J]. Journal of Clinical Hepatology, 2023, 39(11): 2697-2704. doi: 10.3969/j.issn.1001-5256.2023.11.027

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (251) PDF downloads(35)

Value of modified albumin-bilirubin grade in predicting the prognosis of patients with Child-Pugh class A unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization combined with immunotherapy and anti-angiogenic drugs

DOI: 10.12449/JCH241215

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Value of modified albumin-bilirubin grade in predicting the prognosis of patients with Child-Pugh class A unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization combined with immunotherapy and anti-angiogenic drugs

DOI: 10.12449/JCH241215

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content